Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour By Ogkologos - March 18, 2026 316 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANEUVER study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Tafasitamab July 8, 2021 ¿Comer alimentos a la parrilla o asados puede provocar cáncer? September 14, 2023 Intensive Program Helps People Being Screened for Lung Cancer Quit Smoking March 21, 2025 Enhancements to NCI’s SEER Program Creating New Research Opportunities August 23, 2018 Load more HOT NEWS Treatment with a Hypomethylating Agent Can Activate or Up-regulate Oncogenes What to Expect During a Skin Cancer Screening Women Under 35 More Likely to Have Their Breast Cancer Spread NECTIN4 Amplification Predicts Response to Enfortumab Vedotin and Long-Term Survival in...
